PMID- 36992775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 2673-6616 (Electronic)
IS  - 2673-6616 (Linking)
VI  - 3
DP  - 2022
TI  - Elevated ACE Levels Indicate Diabetic Nephropathy Progression or Companied Retina 
      Impaired.
PG  - 831128
LID - 10.3389/fcdhc.2022.831128 [doi]
LID - 831128
AB  - OBJECTIVES: Renin-angiotensin-aldosterone system plays important roles in the 
      development of diabetic nephropathy (DN), and angiotensin converting enzyme (ACE) 
      is the key factor in the process from angiotensin I to angiotensin II, but the 
      variation and roles of serum ACE in DN patients are still unclear. METHODS: 
      Forty-four type 2 diabetes mellitus (T2DM) patients, 75 DN patients, and 36 
      age-gender-matched healthy volunteers were recruited who attended Xiangya 
      Hospital of Central South University in this case control study. Serum ACE levels 
      and other indexes were tested with commercial kit. RESULTS: ACE levels in DN were 
      significantly higher than T2DM and controls (F = 9.66, P < 0.001). Serum ACE 
      levels significantly correlated with UmALB (r = 0.3650, P < 0.001), BUN (r = 
      0.3102, P < 0.001), HbA1c (r = 0.2046, P = 0.0221), ACR (r = 0.4187, P < 0.001), 
      ALB (r = -0.1885, P = 0.0192), and eGFR (r = -0.3955, P < 0.001), and we got an 
      equation that Y = 2.839 + 0.648X(1) + 2.001X(2) + 0.003X(3) - 6.637X(4) 
      +0.416X(5) - 0.134X(6) (Y: ACE; X(1): BUN; X(2): HbA1C; X(3): UmALB; X(4): 
      gender; X(5): ALB; X(6): eGFR, R(2) = 0.655). When DN patients were divided into 
      advanced-stage and early-stage with or without DR, ACE levels would increase when 
      early-stage DN develops into advanced-stage or companied with DR. CONCLUSION: 
      Elevated serum ACE levels may hint DN progression or retina impaired of DN 
      patients.
CI  - Copyright (c) 2022 Huang, Liang, Wang, Ma, Wu, Luo and Yi.
FAU - Huang, Kangkang
AU  - Huang K
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, China.
FAU - Liang, Yunlai
AU  - Liang Y
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Wang, Kun
AU  - Wang K
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Ma, Yating
AU  - Ma Y
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Wu, Jiahui
AU  - Wu J
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, China.
FAU - Luo, Huidan
AU  - Luo H
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, China.
FAU - Yi, Bin
AU  - Yi B
AD  - Department of Clinical Laboratory, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20220512
PL  - Switzerland
TA  - Front Clin Diabetes Healthc
JT  - Frontiers in clinical diabetes and healthcare
JID - 9918266295306676
PMC - PMC10012155
OTO - NOTNLM
OT  - RAAS
OT  - angiotensin converting enzyme
OT  - diabetic nephropathy
OT  - diabetic retinopathy
OT  - type 2 diabetic mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/31 06:00
MHDA- 2023/03/31 06:01
PMCR- 2022/05/12
CRDT- 2023/03/30 02:45
PHST- 2021/12/14 00:00 [received]
PHST- 2022/01/03 00:00 [accepted]
PHST- 2023/03/31 06:01 [medline]
PHST- 2023/03/30 02:45 [entrez]
PHST- 2023/03/31 06:00 [pubmed]
PHST- 2022/05/12 00:00 [pmc-release]
AID - 10.3389/fcdhc.2022.831128 [doi]
PST - epublish
SO  - Front Clin Diabetes Healthc. 2022 May 12;3:831128. doi: 
      10.3389/fcdhc.2022.831128. eCollection 2022.